Alliance Pharma continued its expansion plans with the opening of a new bioanalytical lab in Brisbane, Australia, to support preclinical and clinical testing.
The 20,000-square-foot facility will provide small- and large-molecule bioanalytical services for a region with limited choices for bioanalytical support, the company said in a Dec. 7 press release.
“It will allow biotech companies to work with us in Australia in the early phase and then transfer the knowledge on these assays to other regions to support the later development phases,” Jason (Hao) Wang, Alliance’s site president, Australia, said in the release. “Our objective is to accelerate the growth of our best-in-class portfolio and deliver industry-leading drug development service for our worldwide clients."
The U.K.-based CRO has been on a growth spurt this year. In late September, the company announced four additions to its C-suite to help bolster its growth.
That move followed Alliance’s acquisition in July of U.K.-based CRO Drug Development Solutions for an undisclosed sum.